RPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Royalty Pharma PLC (RPRX) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, positive financial growth trends, and hedge fund interest, making it a solid choice for long-term growth.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 40.098, and moving averages are converging, suggesting no clear trend. Key support is at 45.167, and resistance is at 46.603. The stock is trading near its pivot level of 45.885.
Strong analyst ratings with multiple price target upgrades, including TD Cowen ($50), Morgan Stanley ($61), and Goldman Sachs ($51).
Hedge fund buying increased by 100.83% in the last quarter.
Positive financial growth in Q4 2025, with revenue up 4.78% YoY, net income up 2.88% YoY, and EPS up 6.38% YoY.
High probability of short-term price increase based on historical candlestick patterns.
No recent news or significant insider trading activity.
Technical indicators show bearish momentum with no clear upward trend.
In Q4 2025, Royalty Pharma reported revenue growth of 4.78% YoY to $621.99M, net income growth of 2.88% YoY to $214.21M, and EPS growth of 6.38% YoY to $0.50. Gross margin remained stable at 100%.
Analysts are highly bullish on RPRX, with recent upgrades and price target increases. TD Cowen, Morgan Stanley, Goldman Sachs, UBS, and Citi all maintain Buy or Overweight ratings, citing strong financials, growth potential in the biopharma royalty market, and a robust pipeline of royalty deals.
